Clinical Trials Logo

Filter by:
NCT ID: NCT06333678 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

In this study, the researchers will look at whether having participants switch from durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The researchers will see whether this switch to sotorasib can control LANSCLC longer compared to the treatment approach of staying on durvalumab (and not switching to sotorasib).

NCT ID: NCT06333652 Recruiting - Preeclampsia Clinical Trials

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

NCT ID: NCT06333613 Completed - Visual Acuity Clinical Trials

Evaluation of Acuvue Oasys 1-Day Contact Lenses in New Wearers

Start date: March 26, 2024
Phase: N/A
Study type: Interventional

This is a multi-site, bilateral, dispensing, non-randomized, uncontrolled, unmasked, single arm study to evaluate visual acuity in neophytes.

NCT ID: NCT06333522 Not yet recruiting - Clinical trials for Arthrofibrosis of Knee

Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty

Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of Losartan, an Angiotensin II Receptor Blocker (ARB), on the formation development of arthrofibrosis in patients who have had a primary total knee arthroplasty. This study aims to assess the post-operative range of motion and the incidence of MUA within three months following the index arthroplasty in the treatment arm (losartan) and the control arm.

NCT ID: NCT06333496 Active, not recruiting - Obesity Clinical Trials

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints.

NCT ID: NCT06333288 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Pilot Trial to Evaluate PROblem Solving Therapy and APPLE Watch for College Students

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

The goals of this Pilot Trial are to test the preliminary efficacy of Problom-Solving Therapy (PST)-APPLE Watch in a 2-arm pilot Randomized Control Trial (RCT), vs education only-control to reduce alcohol use disorder symptoms and improve alcohol abstinence.

NCT ID: NCT06333262 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Start date: April 22, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

NCT ID: NCT06333249 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Start date: April 13, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

NCT ID: NCT06333171 Not yet recruiting - Wounds and Injuries Clinical Trials

4-aminopyridine for Skin Wound Healing

Start date: July 2024
Phase: Phase 2
Study type: Interventional

Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults. The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing. The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.

NCT ID: NCT06333067 Recruiting - Lax Skin Clinical Trials

Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators

Start date: October 11, 2023
Phase: N/A
Study type: Interventional

Open-label, non-randomized single-arm prospective, multi-center, self-controlled clinical study with masked evaluation.